Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (267)	4/15/2010 10:47:23 AM
From: John McCarthy	Respond to of 421

My Notes from Roadshow (subject to ERROR) PRICING 3,000 to $5,000 - ?? (thats for a 3 year product) versus $70,000 for Lucentis in SAME time span (They STATE they are going towards LOW price point) Market DME = 300,000 patients a year Get 25% of market = > 1 Billion Market for Alimera 1,600 DOCS in WHOLE MARKET Paraphrase - these doctors are cowboys and quickly uptake NEW METHODOLOGIES 30 Sales Reps (for whole market ) = $15 million in Annual Costs Will pay the $15 million to Psivida when they get IPO money Q3 - 2010 - filing in Europe Again - WATCH THE ROADSHOW Note: If you dumb-down pSivida 20% profit take its really equal to a 14% - 16% ROYALTY on Net Sales (this stated by President of Alimera)